Myeloid sarcoma (MS) is a solid tumor of granulocytic origin with extramedullary localization. This tumor is rare in humans and animals. The diagnostic approach is heterogeneous, and the definitive diagnosis may be difficult to achieve. Primary MS has never been described as a spontaneous neoplasm in companion dogs. Two purebred and 1 mixed-breed dogs, 6- to 11-year-old, developed round cell tumors in the mediastinum, lymph nodes (LNs) and tonsils, and LNs, respectively. Granulocytic origin and exclusion of lymphoid lineage were confirmed by flow cytometry, supported by immunohistochemistry or immunocytochemistry. Pivotal to the diagnosis were positive labeling for myeloid (CD11b, CD14) and hematopoietic precursors (CD34) markers, along with negative labeling for lymphoid markers. Blood and bone marrow infiltration were not detected at initial diagnosis, excluding acute myeloid leukemia. The behavior of these tumors was aggressive, resulting in poor clinical outcomes, even when chemotherapy was attempted.
Granulocytic neoplasm suggestive of primary myeloid sarcoma in 3 dogs / A. Ubiali, V. Martini, S. Comazzi, S. Iussich, B. Miniscalco, A. Poggi, E. Morello, P. Roccabianca, B. Rütgen, C. Zamboni, F. Riondato. - In: VETERINARY PATHOLOGY. - ISSN 0300-9858. - (2024), pp. 3009858241257897.1-3009858241257897.6. [Epub ahead of print] [10.1177/03009858241257897]
Granulocytic neoplasm suggestive of primary myeloid sarcoma in 3 dogs
A. UbialiPrimo
;V. MartiniSecondo
;S. Comazzi;P. Roccabianca;C. ZamboniPenultimo
;
2024
Abstract
Myeloid sarcoma (MS) is a solid tumor of granulocytic origin with extramedullary localization. This tumor is rare in humans and animals. The diagnostic approach is heterogeneous, and the definitive diagnosis may be difficult to achieve. Primary MS has never been described as a spontaneous neoplasm in companion dogs. Two purebred and 1 mixed-breed dogs, 6- to 11-year-old, developed round cell tumors in the mediastinum, lymph nodes (LNs) and tonsils, and LNs, respectively. Granulocytic origin and exclusion of lymphoid lineage were confirmed by flow cytometry, supported by immunohistochemistry or immunocytochemistry. Pivotal to the diagnosis were positive labeling for myeloid (CD11b, CD14) and hematopoietic precursors (CD34) markers, along with negative labeling for lymphoid markers. Blood and bone marrow infiltration were not detected at initial diagnosis, excluding acute myeloid leukemia. The behavior of these tumors was aggressive, resulting in poor clinical outcomes, even when chemotherapy was attempted.File | Dimensione | Formato | |
---|---|---|---|
Ubiali et al2024.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
858.41 kB
Formato
Adobe PDF
|
858.41 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.